SCHEMBL9110223

SCHEMBL9110223

CC(C)(C)OC(=O)Nc1ccc(-c2ccnn2C(=O)OC(C)(C)C)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 4/20 0.52
PSMB8 P28062 1/20 0.50
NAMPT P43490 1/20 0.44
HDAC3 O15379 2/20 0.44
HDAC1 Q13547 2/20 0.44
EGLN2 Q96KS0 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
MAP4K4 O95819 1/20 0.44
PTPN2 P17706 1/20 0.43
PTPN1 P18031 1/20 0.43
PTPN6 P29350 1/20 0.43
PRKDC P78527 1/20 0.43
CD274 Q9NZQ7 1/20 0.43
HDAC10 Q969S8 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4951116 0.81 KDM5A (0.40) NPC1RAB9ASMN1; SMN2BCL2BECN1
SCHEMBL9909930 0.81 NR1H2 (0.39) HDAC1HDAC2NPC1ALDH1A1RAB9A
SCHEMBL6292251 0.78 CYP17A1 (0.40) CYP17A1PSMB8NAMPTPTPN2PTPN1
SCHEMBL20865536 0.77 CYP17A1 (0.68) CYP17A1PSMB8NAMPTHDAC3HDAC1
SCHEMBL13055402 0.75 CYP17A1 (0.59) CYP17A1PSMB8NAMPTMAP4K4ALDH1A1
SCHEMBL4759920 0.75 CYP17A1 (0.79) CYP17A1PSMB8NAMPTHDAC3HDAC1
SCHEMBL28507530 0.74 USP30 (0.43)
SCHEMBL22295001 0.72 CYP17A1 (0.58) CYP17A1PSMB8NAMPTHDAC3HDAC1
SCHEMBL21296771 0.72 MAP2K4 (0.39) NPC1RAB9ASMN1; SMN2
SCHEMBL31306280 0.72 JAK2 (0.53) CYP17A1PSMB8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2464228-B1 SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK SHARP & DOHME (US) 2017-12-06 EP disclosed
EP-2464228-B1 SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK SHARP & DOHME (US) 2017-12-06 EP disclosed
US-8552022-B2 Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment MERCK SHARP & DOHME CORP. (US) 2013-10-08 US disclosed
US-20120142706-A1 SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK SHARP & DOHME LLC 2012-06-07 US disclosed
WO-2011019538-A1 SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK SHARP & DOHME CORP. (US) 2011-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142706-A1 SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT GPR119, GPR27, GCGR CYP17A1 875/4885PSMB8 3288/4885NAMPT 2670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.